Cold-PCR Technology Detects Tumour Mutations Transgenomic has validated the use of its licensed Cold-PCR technology to detect colorectal tumour-associated KRAS mutations that determine efficacy of recently developed therapies. These mutations were detected in plasma samples in which the mutation levels were too low for detection by standard DNA analysis methodologies such as Sanger sequencing. The study, which was performed by Transgenomic's Pharmacogenomics Services Laboratory in Omaha and the company's molecular biology research team in Gaithersburg, consisted of testing DNA extracted from colorectal tumour-matched plasma samples. Screening with standard Sanger sequencing of the plasma samples resulted in only 70 per cent concordance between matched plasma and tumour due to missing KRAS codon 12 and 13 mutations. The samples were enriched by Transgenomic's Cold-PCR mutation enrichment technology before analysis with the Surveyor Scan KRAS assay. Cold-PCR preferentially am...
Posts
Showing posts with the label Mutations